Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Acute otitis media
Epidemiology
Healthcare utilization
Incidence
Pneumococcal conjugate vaccine
United States
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
26 Mar 2022
26 Mar 2022
Historique:
received:
21
06
2021
accepted:
22
02
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
Acute otitis media (AOM) is a leading cause of office visits and antibiotic prescriptions in children. Pneumococcal conjugate vaccines were introduced in the USA in 2000 (7-valent, PCV7) and 2010 (13-valent, PCV13). Expanded valency PCVs are currently under development. To describe the impact of PCVs and quantify the residual burden of AOM, this study estimated annual incidence rates (IRs) of AOM and AOM-related complications and surgical procedures in children < 18 years in the USA before and after the introduction of PCV7 and PCV13. AOM episodes were identified in the IBM MarketScan In the commercially insured population, AOM IRs declined between the pre-PCV7 period (1998-1999) and the late PCV13 period (2014-2018) from 1170.1 to 768.8 episodes per 1000 PY for children < 2 years, from 547.4 to 410.3 episodes per 1000 PY in children 2-4 years, and from 115.6 to 91.8 episodes per 1000 PY in children 5-17 years. The interrupted time series analyses indicated significant immediate or gradual decreases in the early PCV7 period (2001-2005), and gradual increases in the late PCV7 period (2006-2009) in children < 2 years; however, crude IRs trended downward in all time periods. In older children, IRs decreased in the early PCV7 and early PCV13 period (2011-2013), but gradually increased in the late PCV7 period. IRs of AOM-related surgical procedures decreased, and IRs of AOM-related complications increased during the study timeframe. AOM disease burden remains high in children of all ages despite overall reductions in AOM IRs during 1998-2018 following the introduction of PCV7 and PCV13. The impact of investigational PCVs on the disease burden of AOM will likely depend on AOM etiology and circulating pneumococcal serotypes.
Sections du résumé
BACKGROUND
BACKGROUND
Acute otitis media (AOM) is a leading cause of office visits and antibiotic prescriptions in children. Pneumococcal conjugate vaccines were introduced in the USA in 2000 (7-valent, PCV7) and 2010 (13-valent, PCV13). Expanded valency PCVs are currently under development. To describe the impact of PCVs and quantify the residual burden of AOM, this study estimated annual incidence rates (IRs) of AOM and AOM-related complications and surgical procedures in children < 18 years in the USA before and after the introduction of PCV7 and PCV13.
METHODS
METHODS
AOM episodes were identified in the IBM MarketScan
RESULTS
RESULTS
In the commercially insured population, AOM IRs declined between the pre-PCV7 period (1998-1999) and the late PCV13 period (2014-2018) from 1170.1 to 768.8 episodes per 1000 PY for children < 2 years, from 547.4 to 410.3 episodes per 1000 PY in children 2-4 years, and from 115.6 to 91.8 episodes per 1000 PY in children 5-17 years. The interrupted time series analyses indicated significant immediate or gradual decreases in the early PCV7 period (2001-2005), and gradual increases in the late PCV7 period (2006-2009) in children < 2 years; however, crude IRs trended downward in all time periods. In older children, IRs decreased in the early PCV7 and early PCV13 period (2011-2013), but gradually increased in the late PCV7 period. IRs of AOM-related surgical procedures decreased, and IRs of AOM-related complications increased during the study timeframe.
CONCLUSIONS
CONCLUSIONS
AOM disease burden remains high in children of all ages despite overall reductions in AOM IRs during 1998-2018 following the introduction of PCV7 and PCV13. The impact of investigational PCVs on the disease burden of AOM will likely depend on AOM etiology and circulating pneumococcal serotypes.
Identifiants
pubmed: 35346092
doi: 10.1186/s12879-022-07275-9
pii: 10.1186/s12879-022-07275-9
pmc: PMC8962537
doi:
Substances chimiques
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
294Informations de copyright
© 2022. The Author(s).
Références
Vaccine. 2018 Oct 29;36(45):6883-6891
pubmed: 30244873
Clin Infect Dis. 2021 Mar 1;72(5):797-805
pubmed: 32067037
JAMA Pediatr. 2014 Jan;168(1):68-75
pubmed: 24276262
Pediatr Infect Dis J. 2010 Apr;29(4):304-9
pubmed: 19935445
Annu Rev Public Health. 2006;27:235-59
pubmed: 16533116
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
Clin Infect Dis. 2012 Dec;55(12):1673-6
pubmed: 22972864
J Infect Dis. 2008 Apr 1;197(7):1016-27
pubmed: 18419539
BMC Health Serv Res. 2018 May 2;18(1):318
pubmed: 29720156
Eur J Clin Microbiol Infect Dis. 2022 Jan;41(1):37-44
pubmed: 34432166
Pediatr Infect Dis J. 2004 Aug;23(8):732-8
pubmed: 15295223
Pediatr Infect Dis J. 2020 Aug;39(8):763-770
pubmed: 32639460
Glob Pediatr Health. 2017 Dec 21;4:2333794X17749668
pubmed: 29308427
Pediatrics. 2006 Sep;118(3):865-73
pubmed: 16950975
Clin Vaccine Immunol. 2015 May;22(5):459-66
pubmed: 25787137
J Pediatr. 2018 Oct;201:122-127.e1
pubmed: 29958675
Vaccine. 2018 Nov 26;36(49):7479-7486
pubmed: 30385056
Open Forum Infect Dis. 2019 Oct 04;6(11):ofz432
pubmed: 31723568
Pediatr Infect Dis J. 2007 Jun;26(6):468-72
pubmed: 17529860
Pediatrics. 2017 Sep;140(3):
pubmed: 28784702
Lancet. 2012 Apr 14;379(9824):1387-8; author reply 1388-9
pubmed: 22500868
JAMA. 2007 Oct 17;298(15):1772-8
pubmed: 17940232
Am Fam Physician. 2017 Jan 15;95(2):109-110
pubmed: 28084706
J Infect Dis. 2005 Dec 1;192(11):1988-95
pubmed: 16267772
Pediatr Infect Dis J. 2013 Aug;32(8):805-809
pubmed: 23860479
Pediatr Infect Dis J. 2003 Jan;22(1):10-6
pubmed: 12544402
Vaccine. 2010 May 7;28(21):3650-60
pubmed: 20359560
Vaccines (Basel). 2020 Mar 17;8(1):
pubmed: 32192117
Lancet Child Adolesc Health. 2018 Aug;2(8):561-568
pubmed: 30119715
Arch Dis Child Educ Pract Ed. 2015 Aug;100(4):193-7
pubmed: 25395494
Infect Drug Resist. 2014 Jan 10;7:15-24
pubmed: 24453496
MMWR Recomm Rep. 2000 Oct 6;49(RR-9):1-35
pubmed: 11055835
Pediatrics. 2008 Feb;121(2):253-60
pubmed: 18245415
Int J Pediatr Otorhinolaryngol. 2019 Apr;119:96-102
pubmed: 30690309